サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1247441

免疫組織化学の世界市場-2023-2030

Global Immunohistochemistry Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
免疫組織化学の世界市場-2023-2030
出版日: 2023年03月28日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の免疫組織化学の市場規模は、2022年に23億279万米ドルとなり、2030年には42億4,065万米ドルに達すると推定され、予測期間（2023-2030年）にCAGR 8.1%で成長します。

抗体は、免疫組織化学（IHC）として知られるプロセスにおいて、組織セグメント（例えば、肝臓、膵臓、心臓）内の細胞でタンパク質（抗原）を認識するために使用されます。病気検査のために組織サンプルが研究室に届けられたとき、いくつかの特徴を確認することは困難です。顕微鏡で見ると同じ大きさや形の細胞が含まれているように見えても、様々な病気や病気のサブタイプによって挙動が異なり、異なる治療が必要になることがあります。これらの細胞を区別する最も効果的な方法は、細胞上のマーカーとして機能する特定の分子を探すことです。

市場力学

免疫組織化学の世界市場を牽引する主な要因は、がんの発生率と有病率の増加、IHC検査に対する償還の可能性、IHCの技術的進歩として市場が拡大することです。

がんの発生率と有病率の増加が、市場の成長を促進すると予想されます。

Cancerの有病率の増加と、感染症、心血管障害、その他の疾患の診断における免疫組織化学の普及は、いずれもこの市場のかなりのシェアに関連しています。世界保健機関2022によると、Cancerは体のあらゆる部分に影響を及ぼす可能性のあるあらゆる疾患を指す広義の用語です。その他の用語としては、悪性腫瘍や新生物などが使用されています。Cancerは、2020年には世界の死亡原因の第一位となり、推定死亡者数は1,000万人、つまり約6人に1人の割合で死亡すると言われています。

がんの代表的なものに、乳がん、肺がん、結腸がん、直腸がん、前立腺がんがあります。がん関連死の約3分の1は、喫煙、高体重指数、アルコールの摂取、野菜や果物の少ない食事、運動不足が原因となっています。

また、米国国立衛生研究所によると、2020年には、米国で新たに1,806,590人のがん患者が診断され、606,520人がこの病気で死亡すると推定されています。最も一般的ながんは、乳がん、肺および気管支がん、前立腺がん、結腸および直腸がん、皮膚のメラノーマ、膀胱がん、非ホジキンリンパ腫、腎臓および腎盂がん、子宮内膜がん、白血病、すい臓がん、甲状腺がん、肝臓がんです（2020年の推定新規発症数による降順で表示されます）。これらのがん疾患は、免疫化学ツールの需要を増加させる。

熟練した病理医の不足は、市場の成長を妨げると予想されます。

しかし、十分な訓練を受けた病理医がいないことが、市場拡大の制約になっています。病理医は、自動IHCプラットフォームを使用してパラフィン切片の免疫組織化学（IHC）染色を実施し、適切な抗原回収法を適用し、壊れた機器や劣悪な染色に関する問題を解決します。そして、病理医がいなければ、それは不可能でした。訓練を受けていない技術者は、市場にとって邪魔な存在なのです。

COVID-19影響度分析

SARS-CoV-2の発生は、市場拡大のチャンスとなる可能性があることが明らかになりました。数多くの学術機関やバイオ医薬品企業が、免疫蛍光アッセイを有用な診断ツールにするための検討を進めています。COVID-19の流行は、世界の供給ネットワークに大きな障壁をもたらしました。数多くの全国的な封鎖が続き、原材料や完成品の流れが妨げられ、あるいは一時的に遮断され、製造工程に影響を及ぼしています。

しかし、免疫組織化学とin situハイブリダイゼーション法により、ホルマリン固定パラフィン包埋（FFPE）標本中のSARS-CoVおよびSARS-CoV-2ウイルス産物の検出が可能になったことは、2020年12月号のNature誌によると、今後計り知れない価値を持つことになると思われます。コロナウイルスの病原体の調査や動物モデルでの治療研究は、これらの多様な方法をウイルス検出や物質合成に利用することができます。

さらに、COVID-19のパンデミックは、免疫組織化学キットや試薬の入手性に影響を与えたが、COVID-19の研究や診断に使用することで、今後数年間で需要が高まると予測されています。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲について

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • がんの発生率と有病率の増加
      • IHC検査に対する払い戻しの可能性
    • 阻害要因：
      • 熟練した病理医の不足が市場成長の妨げになると予想されます
    • ビジネスチャンス
    • 影響度分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格アナリシス
  • レギュラトリー・アナリシス

第6章 COVID-19の分析

  • 市場におけるCOVID-19の分析
    • COVID-19の市場シナリオの前に
    • 現在のCOVID-19の市場シナリオ
    • COVID-19以降または将来シナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • 結論

第7章 製品別

  • 抗体
    • 試薬
      • 組織染色
      • ブロッキング血清・試薬
      • 固定化試薬
      • 発色性基質
      • 蛋白質分解酵素
      • 有機溶剤
      • 希釈剤
      • その他
    • 設備
      • スライド染色システム
      • スライドスキャナー
      • ティシュープロセッシング・システム
      • その他
    • キット
      • 動物用IHCキット
      • ヒトIHCキット

第8章 アプリケーション別

  • ダイアグノスティックス
  • 薬物検査
  • フォレンジックアプリケーション
  • その他

第9章 エンドユーザー別

  • 病院
  • 診断ラボラトリー
  • 学術・研究機関など
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • U.K.
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢について

  • 主な発展と戦略
  • 企業シェア分析
  • 製品ベンチマーキング
  • 注目の主要企業一覧

第12章 企業プロファイル

  • Danaher Corporation
    • 会社概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • F. Hoffmann-La Roche Ag.
  • BD
  • Agilent Technologies, Inc.
  • Merck Kgaa
  • Bio-Rad Laboratories, Inc.
  • BioGenex
  • Abcam Plc
  • Candor Bioscience Gmbh
  • PerkinElmer, Inc.

第13章 免疫組織化学の世界市場-DataM

目次
Product Code: PH3182

Market Overview

The global Immunohistochemistry market size was valued at US$ 2,302.79 million in 2022 and is estimated to reach US$ 4,240.65 million by 2030, growing at a CAGR of 8.1% during the forecast period (2023-2030).

Antibodies are employed in the process known as immunohistochemistry (IHC) to recognize proteins (antigens) in cells within a tissue segment (for instance, liver, pancreas or heart). Several characteristics are challenging to ascertain when a tissue sample is delivered to a lab for disease testing. Even if they may appear to contain identical cells in size or shape under a microscope, various diseases or disease subtypes may behave differently and call for different treatments. The most effective way to distinguish between these cells is to look for particular molecules that act as markers on them.

Market Dynamics

The major factors driving the global Immunohistochemistry market the market will expand as the growing incidence and prevalence of Cancer, availability of reimbursements for IHC tests and technological advancements in IHC.

Growing incidence and prevalence of Cancer are expected to drive the market's growth.

The growing prevalence of Cancer and the widespread use of immunohistochemistry in diagnosing infectious diseases, cardiovascular disorders, and other diseases are both associated with a substantial share of this market. According to World Health Organization 2022, Cancer is a broad term that refers to any disease that can affect any body part. Other terms used include malignant tumors and neoplasms. Cancer will be the leading cause of mortality worldwide in 2020, with an estimated 10 million deaths, or approximately one in every six.

The most common forms of Cancer include breast, lung, colon, rectum, and prostate. About one-third of cancer-related deaths are caused by smoking, high body mass index, consuming alcohol, eating few fruits and vegetables, and not exercising.

And according to the National Institutes of Health, in 2020, an estimated 1,806,590 new cases of Cancer will be diagnosed in the United States, and 606,520 people will die from the disease. The most common cancers (listed in descending order according to estimated new cases in 2020) are breast cancer, lung and bronchus Cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial Cancer, leukemia, pancreatic Cancer, thyroid cancer, and liver cancer. These conditions of cancer disorders increase the demand for immunochemistry tools.

Lack of skilled pathologists is expected to hamper the market's growth.

However, the market expansion is constrained by the absence of well-trained pathologists. The pathologist uses an automated IHC platform to carry out immunohistochemistry (IHC) stains on paraffin sections, applies the proper antigen retrieval methods, and resolves problems with broken equipment and subpar stains. And without the pathologist, it would not have been possible; untrained technicians are a hindrance to the market.

COVID-19 Impact Analysis

The SARS-CoV-2 outbreak became apparent as a potential window of opportunity for market expansion. Numerous academic institutions and biopharmaceutical businesses are examining the immunofluorescence assay to make it a useful diagnostic tool. The COVID-19 epidemic has caused significant barriers to global supply networks. Numerous nationwide lockdowns continue to impede or even temporarily block the flow of raw materials and completed goods, impacting the manufacturing process.

However, immunohistochemistry and in situ hybridization methods enable the detection of SARS-CoV and SARS-CoV-2 viral products in formalin-fixed paraffin-embedded (FFPE) specimens will be immensely valuable in the future, according to the Nature magazine, December 2020. Studies of coronavirus pathogenesis and therapeutic research in animal models can use these varied methods for virus detection and material synthesis.

Furthermore, the COVID-19 pandemic affected the availability of immunohistochemistry kits and reagents, yet, their use in COVID-19 research and diagnosis is predicted to enhance its demand in the coming years.

Segment Analysis

The diagnostics segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The application segment is the highest market holder in the global immunohistochemistry market. Numerous market players' launches of new products, viral outbreaks, the prevalence of chronic diseases around the world, an increase in point-of-care diagnostics, and quickly advancing technology are major drivers of the segment's growth. The industry and academia continue to find the field appealing despite its rapid evolution. The development and subsequent administration of tailored medication using diagnostic techniques are projected to accelerate market expansion.

In addition, several market players engage in strategic initiatives. For instance, in January 2021, Diaceutics PLC, a company that offers diagnostic tracking, laboratory mapping, testing, and other services, announced a strategic partnership with Canadian Pathology Quality Assurance, a non-profit organization, to advance the development of Neurotrophic Tropomyosin Receptor Kinase (NTRK) IHC proficiency testing. And in June 2021, Amoy Diagnostics Co. Ltd., Riken Genesis Co. Ltd., and Precision Medicine Asia Co. Ltd. released the AmoyDx Pan Lung Cancer PCR Panel. The Ministry of Health, Labour, and Welfare (MHLW) has given the panel the go-ahead for marketing and production in Japan.

Geographical Analysis

North America holds the largest market share in the global Immunohistochemistry market.

North America dominates the global Immunohistochemistry market primarily due to factors like the presence of major companies, the high prevalence of Cancer and other chronic diseases in the area, and the well-established healthcare infrastructure are only a few of the major factors responsible for the market's growth. The existence of significant market participants, the ease with which IHC solutions are accessible, the increased use of technologically advanced IHC instruments, and the arrival of newer IHC solutions all contribute to the market expansion in the North American region.

For instance, in March 2022, Boston Cell Standards, a company dedicated to ensuring that cancer patients receive accurate diagnosis and treatment, announced that it launched the Consortium for Analytic Standardization in Immunohistochemistry (CASI). The new organization is led by an international panel of pathologists and scientists dedicated to improving patient immunohistochemistry (IHC) test accuracy and reproducibility. And in June 2021, PathAI, a U.S.-based provider of AI-powered technology for pathological applications, presented a machine learning-based quality control tool developed for HER2 testing in breast cancer in June 2021 at the American society of clinical oncology virtual scientific program 2021.

Competitive Landscape

The Immunohistochemistry market is moderately competitive with local and global companies' presence. Danaher Corporation, F. Hoffmann-La Roche Ag., BD, Agilent Technologies, Inc., Merck Kgaa, Bio-Rad Laboratories, Inc., BioGenex, Abcam Plc, Candor Bioscience Gmbh, PerkinElmer, Inc. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2021, according to BioGenex, a company that develops, produces, and distributes molecular pathology systems for tumor diagnosis, prognosis, precision medicine, and life science research, three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis have been published. These are CD56, CD163, and CD8A, respectively.

BioGenex.

Overview: BioGenex creates, develops, and sells molecular pathology systems for life science research, precision medicine, and tumor detection and prognosis. Pathology is being revolutionized by BioGenex's market-leading next-generation cytogenetic FISH workflow solution and miRNA system for the characterisation of Cancer of Unknown Primary (CUP) and undifferentiated tumors. The most cutting-edge systems are proprietary fully automated molecular pathology workstations from BioGenex..

Product Portfolio:

IHC Detection Kits: Immunohistochemistry (IHC) Detection Systems are specially designed for the chromogenic detection of antigen-antibody binding reactions with primary antibodies of various sources (mouse or rabbit, IgG or IgM).

The global Immunohistochemistry market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing incidence and prevalence of Cancer.
      • 4.1.1.2. Availability of reimbursements for IHC tests.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of skilled pathologist is expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Antibodies
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
    • 7.2.3. Reagents
      • 7.2.3.1. Histological Stains
      • 7.2.3.2. Blocking Sera and Reagents
      • 7.2.3.3. Fixation Reagents
      • 7.2.3.4. Chromogenic Substrates
      • 7.2.3.5. Proteolytic Enzymes
      • 7.2.3.6. Organic Solvents
      • 7.2.3.7. Diluents
      • 7.2.3.8. Other
    • 7.2.4. Equipment
      • 7.2.4.1. Slide Staining Systems
      • 7.2.4.2. Slide Scanners
      • 7.2.4.3. Tissue Processing Systems
      • 7.2.4.4. Other
    • 7.2.5. Kits
      • 7.2.5.1. Animal IHC Kits
      • 7.2.5.2. Human IHC Kits

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Diagnostics
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Drug Testing
  • 8.4. Forensic Application
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Diagnostic Laboratories
  • 9.4. Academic & Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Danaher Corporation
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. F. Hoffmann-La Roche Ag.
  • 12.3. BD
  • 12.4. Agilent Technologies, Inc.
  • 12.5. Merck Kgaa
  • 12.6. Bio-Rad Laboratories, Inc.
  • 12.7. BioGenex
  • 12.8. Abcam Plc
  • 12.9. Candor Bioscience Gmbh
  • 12.10. PerkinElmer, Inc.

LIST NOT EXHAUSTIVE

13. Global Immunohistochemistry Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us